At The Leukemia & Lymphoma Society (LLS), we celebrate every advancement toward our mission of curing blood cancer and improving the quality of life for patients and their families. Today’s reason to celebrate is the news that the U.S. Food and Drug Administration (FDA) has approved a new treatment for children with a rare type of cancer called ALK-positive anaplastic large cell lymphoma (ALCL).
The LLS Blog invites Aaron, who was diagnosed with peripheral T-cell lymphoma (PTCL), to share his reflections on becoming a self-advocate throughout his cancer experience. Read his powerful first-hand account
Lisa’s world was turned upside-down when she was diagnosed with a rare subtype of lymphoma called nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), which is a type of blood cancer that develops in the lymphatic system. She was immediately admitted to the hospital after her diagnosis to undergo intense treatment, and had to say goodbye to her newborn daughter Quinn, unsure of whether or not she’d ever see her again.
The more we learn more about the underlying mutations that drive cancer the better we get at more precisely hitting those targets with specialized, less toxic treatments. We now understand that a one-size-fits all approach to treating cancer is ineffective for many patients. As The 62nd American Society of Hematology (ASH) annual Meeting ends, let’s take a look at results from studies of targeted therapies that work by interfering with the altered genes that cause cancer cells to grow and spread. Much of the work stems from research supported by LLS.
More than three years after the first chimeric antigen receptor (CAR) T-cell therapy achieved U.S. Food and Drug Administration (FDA) approval, the revolutionary approach that has upended blood cancer treatment continues to generate excitement.